Kyverna Therapeutics, Inc. (KYTX)
7.13
+0.09
(+1.28%)
USD |
NASDAQ |
Sep 18, 16:00
7.13
0.00 (0.00%)
After-Hours: 20:00
Kyverna Therapeutics Enterprise Value : 272.57M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 272.57M |
| September 17, 2026 | 267.03M |
| September 16, 2026 | 258.41M |
| September 15, 2026 | 262.10M |
| September 14, 2026 | 289.19M |
| September 11, 2026 | 280.57M |
| September 10, 2026 | 286.11M |
| September 09, 2026 | 303.97M |
| September 08, 2026 | 330.44M |
| September 04, 2026 | 341.53M |
| September 03, 2026 | 347.68M |
| September 02, 2026 | 364.00M |
| September 01, 2026 | 347.68M |
| August 31, 2026 | 355.38M |
| August 28, 2026 | 348.91M |
| August 27, 2026 | 365.54M |
| August 26, 2026 | 363.69M |
| August 25, 2026 | 377.85M |
| August 24, 2026 | 340.91M |
| August 21, 2026 | 351.99M |
| August 20, 2026 | 334.14M |
| August 19, 2026 | 379.70M |
| August 18, 2026 | 356.92M |
| August 17, 2026 | 384.62M |
| August 14, 2026 | 336.60M |
| Date | Value |
|---|---|
| August 13, 2026 | 331.06M |
| August 12, 2026 | 329.21M |
| August 11, 2026 | 327.36M |
| August 10, 2026 | 319.36M |
| August 07, 2026 | 323.67M |
| August 06, 2026 | 310.74M |
| August 05, 2026 | 303.97M |
| August 04, 2026 | 312.59M |
| August 03, 2026 | 295.96M |
| July 31, 2026 | 283.03M |
| July 30, 2026 | 294.73M |
| July 29, 2026 | 268.87M |
| July 28, 2026 | 294.73M |
| July 27, 2026 | 321.21M |
| July 24, 2026 | 289.81M |
| July 23, 2026 | 282.42M |
| July 22, 2026 | 289.19M |
| July 21, 2026 | 294.12M |
| July 20, 2026 | 279.34M |
| July 17, 2026 | 292.27M |
| July 16, 2026 | 291.65M |
| July 15, 2026 | 312.59M |
| July 14, 2026 | 322.44M |
| July 13, 2026 | 311.97M |
| July 10, 2026 | 355.99M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cartesian Therapeutics, Inc. | 157.45M |
| Allogene Therapeutics, Inc. | 330.04M |
| Beam Therapeutics, Inc. | 1.671B |
| Arrowhead Pharmaceuticals, Inc. | 9.157B |
| Oncolytics Biotech, Inc. | 92.30M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -38.32M |
| Total Expenses (Quarterly) | 38.32M |
| EPS Diluted (Quarterly) | -0.6292 |
| Earnings Yield | -41.17% |
| Normalized Earnings Yield | -41.17 |